| Original language | English |
|---|---|
| Pages (from-to) | 1522-1525 |
| Number of pages | 4 |
| Journal | Clinical Journal of the American Society of Nephrology |
| Volume | 17 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2022 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Journal of the American Society of Nephrology, Vol. 17, No. 10, 10.2022, p. 1522-1525.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease
AU - Vy, Ha My T.
AU - Lin, Bridget M.
AU - Gulamali, Faris F.
AU - Kooperberg, Charles
AU - Graff, Mariaelisa
AU - Wong, Jenny
AU - Campbell, Kirk N.
AU - Matise, Tara C.
AU - Coresh, Josef
AU - Thomas, Fridtjof
AU - Reiner, Alexander P.
AU - Nassir, Rami
AU - Schnatz, Peter F.
AU - Johns, Tanya
AU - Buyske, Steven
AU - Haiman, Christopher
AU - Cooper, Richard
AU - Loos, Ruth J.F.
AU - Horowitz, Carol R.
AU - Gutierrez, Orlando M.
AU - Do, Ron
AU - Franceschini, Nora
AU - Nadkarni, Girish N.
N1 - Funding Information: S. Buyske reports consultancy agreements with Advanced Infrastructure Design, Inc. K.N. Campbell reports consultancy agreements with Calliditas, Goldfinch Bio, Mallinckrodt Pharmaceuticals, Travere, and Vertex; research funding from Aurinia, Goldfinch Bio, and Mallinckrodt Pharmaceuticals; an advisory or leadership role for the medical advisory board of the National Kidney Foundation of Greater New York and the Nephcure Foundation; and board memberships for the National Kidney Foundation and the Nephcure Foundation. J. Coresh reports ownership interest in Healthy.io; consultancy agreements with Healthy.io and SomaLogic; research funding from the National Institutes of Health and the National Kidney Foundation (which receives industry support); and an advisory or leadership role for Healthy.io and the National Kidney Foundation. R. Do reports consultancy agreements with Pensieve Health and Variant Bio; ownership interest in Pensieve Health; and research funding from AstraZeneca and Goldfinch Bio. N. Franceschini reports serving as the Women’s Health Initiative Vice-Chair of the Ancillary Committee and a National Heart, Lung, and Blood Institute TOPMed kidney working group convener and reports serving on the editorial board of American Journal of Physiology-Renal Physiology, the editorial board of Contemporary Clinical Trials, and the Women’s Health Initiative Publication and Presentation Committee. O.M. Gutierrez reports consultancy agreements with QED; research funding from Amgen and GlaxoSmithKline; honoraria from Akebia, Amgen, Ardelyx, AstraZeneca, and Reata; and serving as an associate editor of CJASN. R. Loos reports consultancy agreements with Regen-eron and serving as a board member of the European Association of the Study of Diabetes. G.N. Nadkarni reports consultancy agreements with AstraZeneca, Daiichi Sankyo, GLG Consulting, Qiming Capital, Reata, Renalytix, Siemens Healthineers, and Variant Bio; equity in Data2Wisdom LLC, Doximity, Nexus iConnect, Renaly-tix, and Verici; equity in Pensieve Health as a cofounder; research funding from Renalytix; honoraria from Daiichi Sankyo; patents or royalties from Renalytix; an advisory or leadership role for Renalytix; and speakers bureau for Daiichi Sankyo. P.F. Schnatz reports ownership interest in Evertec Inc., First Interstate Bancsystem Inc., Heico Corp., Mastercard Inc., MBIA Inc., and Block Inc. and an advisory or leadership role for Association of Colposcopy and Cervical Pathology and FaithCare, Inc. F. Thomas reports research funding from Relypsa-Vifor Pharma Inc. and serving as an associate editor of Journal of Statistical Computation and Simulation, Taylor and Francis (no reimbursement). F. Thomas’s spouse serves as an associate editor for Journal of Clinical Oncology (the flagship journal of the American Society for Clinical Oncology: 5-year term from November 1, 2021 to October 31, 2026; contract is with the American Society for Clinical Oncology). All remaining authors have nothing to disclose. Funding Information: This work was supported National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK127139.
PY - 2022/10
Y1 - 2022/10
UR - https://www.scopus.com/pages/publications/85139527988
U2 - 10.2215/CJN.03610322
DO - 10.2215/CJN.03610322
M3 - Letter
C2 - 35948364
AN - SCOPUS:85139527988
SN - 1555-9041
VL - 17
SP - 1522
EP - 1525
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 10
ER -